519 related articles for article (PubMed ID: 8262471)
1. Comparison of complete and incomplete suppression of pituitary-gonadal activity in girls with central precocious puberty: influence on growth and predicted final height. The German-Dutch Precocious Puberty Study Group.
Partsch CJ; Hümmelink R; Peter M; Sippell WG; Oostdijk W; Odink RJ; Drop SL
Horm Res; 1993; 39(3-4):111-7. PubMed ID: 8262471
[TBL] [Abstract][Full Text] [Related]
2. [Comparison between complete and incomplete suppression of the hypophyseal-gonadal axis in girls with central precocious puberty: effect on growth and prospective final height].
Partsch CJ; Hümmelink R; Sippell WG; Oostdijk W; Odink RJ; Drop SL
Monatsschr Kinderheilkd; 1993 Dec; 141(12):935-9. PubMed ID: 8114776
[TBL] [Abstract][Full Text] [Related]
3. Variations in pituitary-gonadal suppression during intranasal buserelin and intramuscular depot-triptorelin therapy for central precocious puberty. Belgian Study Group for Pediatric Endocrinology.
Heinrichs C; Craen M; Vanderschueren-Lodeweyckx M; Malvaux P; Fawe L; Bourguignon JP
Acta Paediatr; 1994 Jun; 83(6):627-33. PubMed ID: 7919761
[TBL] [Abstract][Full Text] [Related]
4. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
Juul A; Scheike T; Nielsen CT; Krabbe S; Müller J; Skakkebaek NE
J Clin Endocrinol Metab; 1995 Oct; 80(10):3059-67. PubMed ID: 7559897
[TBL] [Abstract][Full Text] [Related]
5. Final height in girls with central precocious puberty: comparison of two different luteinizing hormone-releasing hormone agonist treatments.
Antoniazzi F; Cisternino M; Nizzoli G; Bozzola M; Corrias A; De Luca F; De Sanctis C; Rigon F; Zamboni G; Bernasconi S
Acta Paediatr; 1994 Oct; 83(10):1052-6. PubMed ID: 7841703
[TBL] [Abstract][Full Text] [Related]
6. Growth, bone maturation and height prediction after three years of therapy with the slow release GnRH-agonist Decapeptyl-Depot in children with central precocious puberty.
Hümmelink R; Oostdijk W; Partsch CJ; Odink RJ; Drop SL; Sippell WG
Horm Metab Res; 1992 Mar; 24(3):122-6. PubMed ID: 1533604
[TBL] [Abstract][Full Text] [Related]
7. [Growth, development and prediction of body height in children with central precocious puberty after 3 years of therapy with Decapeptyl-Depot, a slow-releasing GnRH agonist].
Hümmelink R; Oostdijk W; Partsch CJ; Odink RJ; Drop SL; Sippell WG
Cesk Pediatr; 1994; 49(1):7-12. PubMed ID: 8124755
[TBL] [Abstract][Full Text] [Related]
8. [Clinical study of subcutaneous administration of gonadotropin-releasing hormone agonist every six weeks in girls with idiopathic central precocious puberty].
Liang Y; Wei H; Zhang JL; Hou L; Luo XP
Zhonghua Er Ke Za Zhi; 2004 Nov; 42(11):845-9. PubMed ID: 15631714
[TBL] [Abstract][Full Text] [Related]
9. Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females.
Bertelloni S; Baroncelli GI; Sorrentino MC; Perri G; Saggese G
Eur J Pediatr; 1998 May; 157(5):363-7. PubMed ID: 9625331
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and treatment of central precocious puberty--can final height be improved? German/Dutch Central Precocious Puberty Study Group.
Sippell WG
Horm Res; 1994; 41 Suppl 2():14-5. PubMed ID: 8088698
[TBL] [Abstract][Full Text] [Related]
11. Long-term treatment of central precocious puberty with a long-acting analogue of luteinizing hormone release hormone (D-Tryp6-GnRH) in monthly injections. Its possible use in normal puberty.
Marcondes JA; Abujamra AC; Minanni SL; Mendonca BB; Nery M; Lerario AC; Pereira MA; Abelin N; Wajchenberg BL
Horm Metab Res; 1993 Feb; 25(2):105-9. PubMed ID: 8458605
[TBL] [Abstract][Full Text] [Related]
12. Long-term results with a slow-release gonadotrophin-releasing hormone agonist in central precocious puberty. Dutch-German Precocious Puberty Study Group.
Oostdijk W; Drop SL; Odink RJ; Hümmelink R; Partsch CJ; Sippell WG
Acta Paediatr Scand Suppl; 1991; 372():39-45; discussion 46. PubMed ID: 1833950
[TBL] [Abstract][Full Text] [Related]
13. Final height, gonadal function and bone mineral density of adolescent males with central precocious puberty after therapy with gonadotropin-releasing hormone analogues.
Bertelloni S; Baroncelli GI; Ferdeghini M; Menchini-Fabris F; Saggese G
Eur J Pediatr; 2000 May; 159(5):369-74. PubMed ID: 10834524
[TBL] [Abstract][Full Text] [Related]
14. [Effect of treatment with gonadotropin releasing hormone analogues in girls with idiopathic central precocious puberty].
Ságodi L; Sólyom E; Lombay B; Almási A; Vámosi I
Orv Hetil; 2012 Mar; 153(11):418-24. PubMed ID: 22390866
[TBL] [Abstract][Full Text] [Related]
15. Treatment of central precocious puberty with an intranasal analogue of GnRH (Buserelin).
Bourguignon JP; Van Vliet G; Vandeweghe M; Malvaux P; Vanderschueren-Lodeweyckx M; Craen M; Du Caju MV; Ernould C
Eur J Pediatr; 1987 Nov; 146(6):555-60. PubMed ID: 3123239
[TBL] [Abstract][Full Text] [Related]
16. Combined therapy with GnRH analog plus growth hormone in central precocious puberty.
Pucarelli I; Segni M; Ortore M; Moretti A; Iannaccone R; Pasquino AM
J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():811-20. PubMed ID: 10969926
[TBL] [Abstract][Full Text] [Related]
17. Treatment of true precocious puberty with a potent luteinizing hormone-releasing factor agonist: effect on growth, sexual maturation, pelvic sonography, and the hypothalamic-pituitary-gonadal axis.
Styne DM; Harris DA; Egli CA; Conte FA; Kaplan SL; Rivier J; Vale W; Grumbach MM
J Clin Endocrinol Metab; 1985 Jul; 61(1):142-51. PubMed ID: 3923027
[TBL] [Abstract][Full Text] [Related]
18. Accelerated versus slowly progressive forms of puberty in girls with precocious and early puberty. Gonadotropin suppressive effect and final height obtained with two different analogs.
Lanes R; Soros A; Jakubowicz S
J Pediatr Endocrinol Metab; 2004 May; 17(5):759-66. PubMed ID: 15237711
[TBL] [Abstract][Full Text] [Related]
19. Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty.
Carel JC; Roger M; Ispas S; Tondu F; Lahlou N; Blumberg J; Chaussain JL
J Clin Endocrinol Metab; 1999 Jun; 84(6):1973-8. PubMed ID: 10372696
[TBL] [Abstract][Full Text] [Related]
20. Factors determining normal adult height in girls with gonadotropin-dependent precocious puberty treated with depot gonadotropin-releasing hormone analogs.
Brito VN; Latronico AC; Cukier P; Teles MG; Silveira LF; Arnhold IJ; Mendonca BB
J Clin Endocrinol Metab; 2008 Jul; 93(7):2662-9. PubMed ID: 18460564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
